Novera Cagrilintide 5mg+Semaglutide 5mg

Novera Cagrilintide 5mg+Semaglutide 5mg is a fixed dose combination of a long acting amylin analogue (cagrilintide) and a GLP-1 receptor agonist (semaglutide), studied for its effects on body weight reduction, appetite regulation, blood glucose control, and cardiometabolic markers. CagriSema is the subject of the REDEFINE phase 3 programme: REDEFINE 1 randomised 3417 adults with overweight or obesity, and REDEFINE 2 randomised 1206 adults who also had type 2 diabetes.

Cagrilintide has no marketing authorisation as a single agent, and neither does the fixed combination. Semaglutide alone is an approved medicine for type 2 diabetes and chronic weight management. This product is supplied for laboratory research use only and is not an approved medicine.

What Novera Cagrilintide 5mg+Semaglutide 5mg Is

Cagrilintide is a long-acting amylin analog under investigation for weight management. It is a lipidated analogue of human amylin reported by Kruse et al. (2021, Journal of Medicinal Chemistry), selected from a structure-activity series aimed at the amyloid-fibril formation that makes amylin itself difficult to develop as a drug. These changes reduce beta-sheet aggregation and amyloid fibril formation while extending the half-life to support once-weekly dosing, distinguishing cagrilintide from both endogenous amylin and the earlier-generation analogue pramlintide.

Semaglutide mimics endogenous glucagon-like peptide-1 but includes fatty acid conjugation and sequence modifications that resist dipeptidyl peptidase-4 degradation. Cagrilintide and semaglutide target different hormone pathways to manage appetite: cagrilintide acts through amylin receptors (AMY1, AMY2, AMY3) and the calcitonin receptor, while semaglutide activates the GLP-1 receptor. Researchers value this compound because each therapy individually engages distinct satiety and glucose-regulatory circuits, and their pairing allows investigation of whether combined signaling yields superior outcomes beyond what either pathway achieves alone.

Why Researchers Study Cagrilintide 5mg+Semaglutide 5mg

The combination targets both blood glucose control and energy balance through complementary receptor systems. Amylin receptor activation reduces post-prandial glucagon, delays gastric emptying, and promotes satiety, while GLP-1 receptor agonism enhances insulin secretion and suppresses caloric intake. The combination therapy of cagrilintide and semaglutide may produce superior weight loss results compared to semaglutide alone, a hypothesis tested across multiple clinical trials and preclinical models.

REDEFINE 1: CagriSema 2.4 mg in Adults With Overweight or Obesity

The REDEFINE 1 trial randomised 3417 adults with overweight or obesity but without diabetes to once-weekly subcutaneous CagriSema (semaglutide 2.4 mg plus cagrilintide 2.4 mg), one of the monotherapies, or placebo over 68 weeks (Garvey et al., 2025, New England Journal of Medicine). CagriSema outperformed placebo in weight loss efficacy: the treatment group achieved a mean body weight reduction of 20.4% versus 3.0% for the placebo group, with an estimated difference of -17.3 percentage points (95% CI, -18.1 to -16.6; P<0.001). The proportion of study participants achieving clinically meaningful weight loss of 20% or more was significantly higher with CagriSema versus placebo.

Gastrointestinal adverse events were reported by 79.6% of the CagriSema group against 39.9% of the placebo group in REDEFINE 1, and were mainly transient and mild to moderate in severity (Garvey et al., 2025).

“Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo.” (Garvey et al., 2025, New England Journal of Medicine, REDEFINE 1)

Weight Reduction Against the Monotherapy Arms

The headline -20.4% comes from the treatment-policy estimand, which counts every randomised participant regardless of adherence; that is the estimand the coprimary endpoint was built on. The monotherapy arms in the same trial reached -14.9% with semaglutide 2.4 mg and -11.5% with cagrilintide 2.4 mg, so the combination added roughly 5.5 percentage points over the stronger single agent (Garvey et al., 2025).

Every one of these figures is combination data. REDEFINE 1 was not designed to apportion the effect between cagrilintide and semaglutide, so no number on this page can be read as the contribution of either component on its own.

Cardiometabolic Outcomes and Obesity Treatment Primary Endpoint

Beyond body weight, the REDEFINE trials measured cardiometabolic secondary endpoints. The clearest published figure is glycaemic: in REDEFINE 2, 73.5% of the CagriSema group reached a glycated haemoglobin of 6.5% or less at week 68, against 15.9% on placebo (Davies et al., 2025, New England Journal of Medicine).

In REDEFINE 2, 1206 adults with a body-mass index of 27 or more, a glycated haemoglobin of 7 to 10% and type 2 diabetes were randomised 3:1 to CagriSema or placebo for 68 weeks. Mean body weight changed by -13.7% versus -3.4% (estimated difference -10.4 percentage points; P less than 0.001), with gastrointestinal adverse events in 72.5% and 34.4% of the two groups respectively (Davies et al., 2025, New England Journal of Medicine).

Once-weekly CagriSema “resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.” (Davies et al., 2025, New England Journal of Medicine, REDEFINE 2)

Preclinical Models Supporting Combination Mechanism

Rodent studies using diet-induced obesity (DIO) models clarify how the combination works at the energy-balance level. Jacobsen et al. (2025, Nature Metabolism) quantified this in rats: CagriSema produced 12% weight loss with a 39% reduction in food intake, while pair-feeding produced less weight loss and matching the weight loss by diet alone required a 51% cut in food intake. Gabery et al. (2025, Life Sciences) characterized the tool compound 0839, an amylin analogue with a sequence similar to cagrilintide, and demonstrated that it potentiated semaglutide’s effects on food intake and fat mass in DIO mice and rats.

“approximately one-third of CagriSema’s weight loss efficacy arises from an effect on energy expenditure, the blunting of metabolic adaptation” (Jacobsen et al., 2025, Nature Metabolism)

Animal-only findings on energy expenditure and body composition do not confirm identical effects in humans. Preclinical work establishes mechanism plausibility, but species differences in metabolic rate and receptor density limit direct translation. No non-human primate data for the fixed combination have been published.

How Cagrilintide 5mg+Semaglutide 5mg Compares With Related Compounds

A researcher asking whether amylin-pathway activation adds anything over GLP-1 alone would select this combination, and would have to run both monotherapies in parallel: without those arms the combination says nothing about either component. In REDEFINE 1 the combination beat semaglutide 2.4 mg alone by roughly 5.5 percentage points of body weight. No head-to-head trial against tirzepatide has been published in a peer-reviewed journal, so the two cannot be ranked against one another from the literature.

What Research on Cagrilintide 5mg+Semaglutide 5mg Does Not Establish

• Long-term cardiovascular outcomes such as major adverse cardiovascular events or mortality have not been reported for CagriSema, despite reductions in surrogate markers like systolic blood pressure. Data on established cardiovascular disease endpoints are absent from published trials.

• No head-to-head trial against tirzepatide has been published in a peer-reviewed journal. Sponsor announcements about REDEFINE 4 have circulated, but until the trial is published nothing about that comparison can be stated as a result, and nothing is known about the combination beyond the 68-week horizon of REDEFINE 1 and 2.

• Animal-only evidence on energy expenditure preservation, fat-versus-lean mass changes, and food-intake suppression does not confirm identical effects in humans.

• Every published CagriSema figure is combination data. Neither REDEFINE trial was designed to attribute an effect to cagrilintide or to semaglutide separately, and the cagrilintide monotherapy arm in REDEFINE 1 was a tenth the size of the combination arm, so no number on this page belongs to one component.

• Neither component is on the 2026 WADA Prohibited List. Amylin analogues such as cagrilintide and GLP-1 receptor agonists such as semaglutide are not named on it, and no class entry covers them.

Where to Buy Novera Cagrilintide 5mg+Semaglutide 5mg

Licensed laboratory professionals looking to buy cagrilintide semaglutide for research can order Novera Cagrilintide 5mg+Semaglutide 5mg through this store.

• Estimated delivery time 3 to 7 days.

• Free shipping on orders over $750.

• All US import fees and tariffs are covered by Ogomed, so the buyer pays nothing extra; customs checks under the new US import rules can add a little time to delivery.

• Price match: if the same product is listed for less elsewhere, Ogomed will try to match it.

• Support by phone +1-650-457-5621 and email, 10am to 6pm EST.

• Sold to licensed professionals, for laboratory research use only.

This product is sold to licensed professionals for research use only.

References

1. Garvey, W. T., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 393(7), 635-647. DOI: 10.1056/NEJMoa2502081
2. Davies, M. J., et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England Journal of Medicine, 393(7), 648-659. DOI: 10.1056/NEJMoa2502082
3. Kruse, T., et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry, 64(15), 11183-11194. DOI: 10.1021/acs.jmedchem.1c00565
4. Jacobsen, J. M., et al. (2025). CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure. Nature Metabolism, 7(7), 1322-1329. DOI: 10.1038/s42255-025-01324-8
5. Gabery, S., et al. (2025). Characterization of 0839: A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide. Life Sciences, 378, 123845. DOI: 10.1016/j.lfs.2025.123845